• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Too Much, Too Little, or Just Right? Obesity and Dosing of Targeted Therapies in Breast Cancer.

作者信息

Cao Chao, Ligibel Jennifer A

机构信息

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.

出版信息

J Clin Oncol. 2023 Nov 20;41(33):5090-5092. doi: 10.1200/JCO.23.01516. Epub 2023 Oct 5.

DOI:10.1200/JCO.23.01516
PMID:37797274
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10666978/
Abstract
摘要

相似文献

1
Too Much, Too Little, or Just Right? Obesity and Dosing of Targeted Therapies in Breast Cancer.过多、过少还是恰到好处？肥胖与乳腺癌靶向治疗的剂量
J Clin Oncol. 2023 Nov 20;41(33):5090-5092. doi: 10.1200/JCO.23.01516. Epub 2023 Oct 5.
2
The impact of actual body weight-based chemotherapy dosing and body size on adverse events and outcome in older patients with breast cancer: Results from Cancer and Leukemia Group B (CALGB) trial 49907 (Alliance A151436).基于实际体重的化疗剂量和体型对老年乳腺癌患者不良事件和结局的影响：癌症和白血病组 B（CALGB）试验 49907（Alliance A151436）的结果。
J Geriatr Oncol. 2018 May;9(3):228-234. doi: 10.1016/j.jgo.2017.11.007. Epub 2017 Dec 8.
3
Impact of obesity on clinical outcomes in hormone receptor-positive breast cancer: a systematic review.肥胖对激素受体阳性乳腺癌临床结局的影响：系统评价。
Breast Cancer. 2021 May;28(3):755-764. doi: 10.1007/s12282-020-01213-w. Epub 2021 Jan 11.
4
Obesity and endocrine therapy resistance in breast cancer: Mechanistic insights and perspectives.肥胖与乳腺癌内分泌治疗抵抗：机制见解与展望。
Obes Rev. 2022 Feb;23(2):e13358. doi: 10.1111/obr.13358. Epub 2021 Sep 24.
5
Obesity and breast cancer: mechanisms and therapeutic implications.肥胖与乳腺癌：机制及治疗意义
Front Biosci (Elite Ed). 2012 Jun 1;4(7):2515-24. doi: 10.2741/e562.
6
Obesity, insulin resistance and breast cancer outcomes.肥胖、胰岛素抵抗与乳腺癌预后
Breast. 2015 Nov;24 Suppl 2:S56-9. doi: 10.1016/j.breast.2015.07.014. Epub 2015 Aug 15.
7
Breast cancer adjuvant chemotherapy dosing in obese patients: dissemination of information from clinical trials to clinical practice.肥胖患者的乳腺癌辅助化疗剂量：从临床试验到临床实践的信息传播
Cancer. 2008 May 15;112(10):2159-65. doi: 10.1002/cncr.23416.
8
Obesity, tamoxifen use, and outcomes in women with estrogen receptor-positive early-stage breast cancer.肥胖、他莫昔芬的使用与雌激素受体阳性早期乳腺癌女性的预后
J Natl Cancer Inst. 2003 Oct 1;95(19):1467-76. doi: 10.1093/jnci/djg060.
9
Effect of obesity on prognosis after early-stage breast cancer.肥胖对早期乳腺癌预后的影响。
J Clin Oncol. 2011 Jan 1;29(1):25-31. doi: 10.1200/JCO.2010.29.7614. Epub 2010 Nov 29.
10
Breast cancer microenvironment and obesity: challenges for therapy.乳腺癌微环境与肥胖：治疗面临的挑战。
Cancer Metastasis Rev. 2022 Sep;41(3):627-647. doi: 10.1007/s10555-022-10031-9. Epub 2022 Apr 18.

引用本文的文献

1
Palbociclib in adults aged 70 years and older with advanced breast cancer: A phase 2 multicenter trial (Alliance A171601).帕博西尼在 70 岁及以上晚期乳腺癌成人患者中的应用：一项多中心 2 期试验（Alliance A171601）。
J Geriatr Oncol. 2024 Jul;15(6):101813. doi: 10.1016/j.jgo.2024.101813. Epub 2024 Jun 8.

本文引用的文献

1
Impact of BMI in Patients With Early Hormone Receptor-Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial.帕拉斯研究中 BMI 对接受内分泌治疗联合或不联合哌柏西利的早期激素受体阳性乳腺癌患者的影响。
J Clin Oncol. 2023 Nov 20;41(33):5118-5130. doi: 10.1200/JCO.23.00126. Epub 2023 Aug 9.
2
Postdiagnosis body fatness, weight change and breast cancer prognosis: Global Cancer Update Program (CUP global) systematic literature review and meta-analysis.诊断后体脂肪、体重变化与乳腺癌预后：全球癌症更新计划（CUP global）系统文献回顾与荟萃分析。
Int J Cancer. 2023 Feb 15;152(4):572-599. doi: 10.1002/ijc.34322. Epub 2022 Oct 24.
3
Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03).帕博西尼联合辅助内分泌治疗激素受体阳性/人表皮生长因子受体 2 阴性早期乳腺癌的 PALbociclib 合作辅助研究中的治疗暴露和停药（PALLAS/AFT-05/ABCSG-42/BIG-14-03）。
J Clin Oncol. 2022 Feb 10;40(5):449-458. doi: 10.1200/JCO.21.01918. Epub 2022 Jan 7.
4
Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer.MONALEESA-2、-3 和 -7 随机试验中激素受体阳性、HER2 阴性晚期乳腺癌的剂量减少的安全性和疗效影响。
Br J Cancer. 2021 Aug;125(5):679-686. doi: 10.1038/s41416-021-01415-9. Epub 2021 Jun 22.
5
Appropriate Systemic Therapy Dosing for Obese Adult Patients With Cancer: ASCO Guideline Update.适合癌症肥胖成年患者的系统治疗剂量：ASCO 指南更新。
J Clin Oncol. 2021 Jun 20;39(18):2037-2048. doi: 10.1200/JCO.21.00471. Epub 2021 May 3.
6
The impact of obesity on neuropathy outcomes for paclitaxel- and oxaliplatin-treated cancer survivors.肥胖对接受紫杉醇和奥沙利铂治疗的癌症幸存者神经病变结局的影响。
J Cancer Surviv. 2022 Apr;16(2):223-232. doi: 10.1007/s11764-021-01012-y. Epub 2021 Feb 27.
7
Association of Obesity With Breast Cancer Outcome in Relation to Cancer Subtypes: A Meta-Analysis.肥胖与乳腺癌结局的相关性：基于癌症亚型的荟萃分析。
J Natl Cancer Inst. 2021 Nov 2;113(11):1465-1475. doi: 10.1093/jnci/djab023.
8
Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study.帕博西尼联合辅助内分泌治疗早期乳腺癌（PALLAS）：多中心、开放标签、随机、III 期研究的中期分析。
Lancet Oncol. 2021 Feb;22(2):212-222. doi: 10.1016/S1470-2045(20)30642-2. Epub 2021 Jan 15.
9
Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE).阿贝西利联合内分泌治疗用于 HR+、HER2-、淋巴结阳性、高危、早期乳腺癌的辅助治疗（monarchE）。
J Clin Oncol. 2020 Dec 1;38(34):3987-3998. doi: 10.1200/JCO.20.02514. Epub 2020 Sep 20.
10
Clinical Implications of Body Mass Index in Metastatic Breast Cancer Patients Treated With Abemaciclib and Endocrine Therapy.体质量指数在阿贝西利联合内分泌治疗转移性乳腺癌患者中的临床意义。
J Natl Cancer Inst. 2021 Apr 6;113(4):462-470. doi: 10.1093/jnci/djaa116.